Safety and efficacy of ashwagen (a standardized withania somnifera extract) in stress and anxiety with hypertension and associated cardiometabolic risk factors: a randomized, placebo-controlled trial.
StressMay 9, 2026 (epub)
Amrit Pattojoshi, Sudeep Kumar Patra, S A Idrees et al.
✦ AI-curated · Sources linked
In 30 seconds
This randomized, double-blind, placebo-controlled Phase III trial evaluated the safety and efficacy of Ashwagen®, a standardized Withania somnifera extract, in 60 patients with stress, anxiety, and pre-existing hypertension. The study found that Ashwagen® significantly reduced anxiety and stress markers, with HAM-A, GAD-7, and PSS scores decreasing by 26.94%, 50.77%, and 30.47%, respectively, compared to placebo.
Key findings
- HAM-A, GAD-7, and PSS scores decreased by 26.94%, 50.77%, and 30.47% in the Ashwagen® group.
- Cortisol levels declined by 28.99% in patients taking Ashwagen®.
- Triglycerides decreased by 13.00% with Ashwagen® treatment.
- No serious adverse events were reported during the trial.
Why it matters
The findings suggest that Ashwagen® may serve as a safe and effective adjunctive treatment for managing stress and anxiety in patients with hypertension, addressing both psychological and physiological aspects of these conditions.